Verrica 獲得 EMA 正面回饋，支持 YCANTH MAA 申請

來源摘錄

EX-99.1 2 d99039dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results – Company reports $14.3 million in revenue in Q3’25, consisting of $3.6 million in YCANTH ® revenue and $10.7 million of license and collaboration revenue – – Reports positive feedback from the FDA and alignment regarding the study design of a Phase 3 program for VP-315 in basal cell carcinoma; Company presented new data on VP-315 at the recent Society for Immunotherapy of Cancer conference – – Received positive feedback from European Medicines Agency that supports a Marketing Authorization Application filing for YCANTH for molluscum without need for additional Phase 3 studies – – Received $10 million cash milestone payment for approval of YCANTH for mollus

SEC 8-K

此資產的更多資訊

值得注意

2026年6月22日

下午12:05

VRCAVerrica Pharmaceuticals

Verrica 啟動 COVE-3 第三期試驗，以 YCANTH 治療常見疣

臨床試驗登錄異動公司新聞稿

值得注意

2026年3月11日

下午12:08

VRCAVerrica Pharmaceuticals

Verrica 啟動 YCANTH 治療常見疣的 Phase 3 試驗；首名患者於 2025 年 12 月給藥

臨床試驗登錄異動SEC 8-K